A safe and effective method for pacemaker implantation in children

Axillary vein puncture for device implantation and use of 4F catheter-delivered pacing leads in children

Hania Burgan, Henri Sunthorn, Haran Burri
Cardiology service, University Hospital of Geneva, Switzerland

Summary

Background: Contrast-guided axillary vein puncture has gained popularity for pacemaker and implantable cardioverter defibrillator (ICD) implantation in adults owing to its low risk profile, and could be an alternative to subclavian vein puncture, which is commonly performed in children. The Medtronic 3830 lead is a 4.1F lumenless catheter-delivered lead which may be particularly well-suited for use in the paediatric population because of the reduction in intravascular material and possibility for selective-site lead placement in complex anatomies.

Methods: Data on paediatric patients at our institution aged <15 years who underwent transvenous device implantation using contrast-guided axillary vein puncture were retrieved. Contrast-guided axillary vein puncture was performed in all patients as the primary approach under general anaesthesia.

Results: We retrieved data from 15 patients (7 males), aged 7.7 ± 4.1 yr (range 2–15 yr) at the time of intervention, and weighing 23.0 ± 9.6 kg (range 11.3–38.0 kg). Axillary vein puncture was successful in all patients. We placed 9 right atrial leads, 13 right ventricular pacing leads, 1 right ventricular ICD lead and 1 coronary sinus lead. A 3830 lead was successfully implanted in all 12 patients in whom this lead was intended. There were no procedure-related complications and lead electrical parameters were within normal limits in all patients after a mean follow-up of 13 months.

Conclusion: Contrast-guided axillary vein puncture is a safe and effective method for pacemaker implantation in children. Furthermore, the thin-bodied 3830 lead provides stable pacing parameters while reducing the bulk of intravascular material.

Key words: pacemaker implantation; paediatric; axillary vein puncture; pacemaker lead

Introduction

In children requiring pacemakers and implantable cardioverter defibrillators (ICDs), transvenous leads offer several advantages compared with surgically-placed epicardial leads: a less invasive approach (avoiding repeat pericardiotomy in patients having undergone cardiac surgery), lower capture thresholds (resulting in greater battery longevity) and fewer long-term lead failures [1]. The most common vascular access route for transvenous lead implantation in children is by subclavian vein puncture. The risks inherent to this approach include pneumothorax, haemothorax and subclavian crush, which may be minimised by using contrast-guided axillary vein puncture. We have been performing axillary vein puncture as a first-line approach in adults for over a decade, and have also been applying this technique in the paediatric population, mainly in conjunction with use of a thin (4.1F) SelectSecure model 3830 lead (Medtronic Inc, Minneapolis, MN, USA). The use of this lead in paediatric patients is particularly interesting due to its excellent performance, with a 99% failure-free survival at 5 years according to the manufacturer’s product performance report in adults [2], its small diameter (which may reduce venous obstruction) [3], and its flexibility (which may minimise tricuspid valve dysfunction). The lead is lumenless with a central cable design, which means that a stylet cannot be inserted for positioning. A deflectable guiding catheter must be used for lead placement, which also allows contrast injection and selective-site pacing in complex anatomies.

Our aims were (1.) to evaluate contrast-guided axillary vein puncture for lead implantation in children, and (2.) to report our experience with the 3830 lead in our paediatric patient population.
Methods

Data collection
Children who underwent endocardial pacemaker or ICD implantation via axillary vein puncture at our institution were included in the study. Data were retrospectively retrieved from the electronic database of the University Hospital of Geneva from January 2008 to August 2014. The device database (Cardioreport, Medireport, Paris, France) was searched for data on devices implanted in all patients aged 15 years or less, with data exported to an XL file. Relevant patients were retrieved by analysing the lead implantation access (transvenous vs epicardial) and the lead model. For relevant patients, the hospital electronic medical records were analysed for clinical data. The electrical parameters of the leads (bipolar capture thresholds, sensing amplitude and impedance) at implantation and at the last follow-up were extracted. Chest X-rays were retrieved from the hospital electronic medical records to confirm final lead position. The study was approved by the institutional ethics committee.

Implant procedure

Contrast-guided axillary vein puncture
All procedures were performed under general anaesthesia. An incision was made parallel and slightly medial to the deltopectoral groove, with blunt dissection to the pectoralis major muscle and prepectoral (or retropectoral in the case of ICD implantation) pocket creation. The axillary vein was visualised under fluoroscopy by use of a bolus injection of 10 cc of semidiluted contrast via a venous catheter placed ipsilateral to the side of pacemaker implantation. The vein was punctured during the contrast injection by insertion of an 18G needle (a micropuncture kit was used in the patient with the lowest body weight) while connected to a 10 cc syringe half-filled with saline, under continuous aspiration. The puncture was performed during posteroanterior fluoroscopy (at 8 frames/s). The needle was aligned parallel to and overlying the opacified axillary vein before it was slowly advanced at an approximately 20°–30° angle through the pectoralis major muscle (fig. 1). The lower border of the first rib was sometimes reached with the needle (this marks the limit of the axillary vein and the extrathoracic subclavian vein), but care was taken never to cross the upper border of the first rib because of the risk of pneumothorax. Slight blanching of the opacified vein at the needle-tip heralded puncture of the vein, which was sometimes traversed, with aspiration of blood during careful withdrawal of the needle. As soon as a small quantity of blood was freely aspirated, a 0.035” J-wire was inserted into the axillary vein down to the inferior vena cava. In all but one case with multiple leads, separate punctures were performed under fluoroscopy, using the first guidewire as a landmark (a single puncture for introducing two leads was used, owing to the difficulty of accessing the axillary vein by means of a second stick after the first puncture).
**Lead placement**

In cases with conventional leads, the implantation was performed according to the standard technique. A subset of patients had implantation of the Medtronic 3830 Select Secure lead, which requires a deflectable 8.4F guiding catheter (fig. 2) as there is no lumen to insert a stylet. The guiding catheter was advanced over a 0.035” J-wire into the right atrium or the right ventricle according to the targeted chamber. The lead is available in two lengths: 59 cm and 69 cm (the extended length is designed to accommodate the guiding catheter), but only the shorter length was used. Atrial leads were implanted in the right atrial appendage. Right ventricular leads were implanted in the apical region (towards the septum). We avoided placing the leads in the mid-septum in order to avoid unintentionally screwing the lead through the septal leaflet or the subvalvular apparatus of the tricuspid valve in these small hearts. The lead has a fixed helix, and was fixated after exposing the lead tip by approximately 1 cm out of the guiding catheter and observing slight buckling of the lead, which indicated contact (visualisation of some current of injury on the electrograms before lead fixation also indicated good contact). The lead body was rotated four to six turns or until slight torque build-up was felt. The guiding catheter was then withdrawn to test for lead stability by pushing the lead, and the electrical parameters were tested after having verified presence of an adequate current of injury. Loops were created in the right atrium to accommodate for future growth and the guiding catheter was then slit (fig. 3). Where multiple leads were implanted, the ventricular lead was implanted first, the guiding catheter slit and the lead fixated with a nonabsorbable suture on the pectora-

**Figure 3:** Final position of SelectSecure 3830 leads positioned in the right atrium and right ventricle, with loops to accommodate for future growth. Image from patient 9 (age 14 yr, weight 32.4 kg, height 154 cm)

**Table 1:** Patient population data.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
<th>Indication</th>
<th>Heart disease</th>
<th>Number of leads</th>
<th>Atrial lead</th>
<th>Ventricular lead</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9</td>
<td>M</td>
<td>34.8</td>
<td>142</td>
<td>AVB III</td>
<td>Congenital lupus</td>
<td>1</td>
<td>3830</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>M</td>
<td>11.3</td>
<td>82.5</td>
<td>AVB III</td>
<td>Aortic valve stenosis</td>
<td>2</td>
<td>3830</td>
<td>3830</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>F</td>
<td>38.0</td>
<td>138</td>
<td>AVB III</td>
<td>Atioventricular canal</td>
<td>1</td>
<td>3830</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>15</td>
<td>F</td>
<td>32.0</td>
<td>164</td>
<td>AVB III</td>
<td>Mitral valve and tricuspid valve stenosis</td>
<td>1</td>
<td>3830</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>M</td>
<td>20.5</td>
<td>116</td>
<td>AVB III</td>
<td>Mitochondrial disease</td>
<td>2</td>
<td>3830</td>
<td>3830</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>F</td>
<td>12.5</td>
<td>90.5</td>
<td>AVB III</td>
<td>Transposition of the great vessels</td>
<td>2</td>
<td>3830</td>
<td>SJM 1084T</td>
</tr>
<tr>
<td>7</td>
<td>6</td>
<td>F</td>
<td>13.8</td>
<td>106</td>
<td>AVB III</td>
<td>Tetralogy of Fallot</td>
<td>1</td>
<td>3830</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>F</td>
<td>18.2</td>
<td>95</td>
<td>AVB III</td>
<td>Atioventricular canal</td>
<td>2</td>
<td>3830</td>
<td>3830</td>
</tr>
<tr>
<td>9</td>
<td>14</td>
<td>M</td>
<td>32.4</td>
<td>154</td>
<td>AVB III</td>
<td>Mitral valve insufficiency</td>
<td>2</td>
<td>3830</td>
<td>3830</td>
</tr>
<tr>
<td>10</td>
<td>13</td>
<td>M</td>
<td>36.8</td>
<td>154</td>
<td>AVB III</td>
<td>Tricuspid valve stenosis</td>
<td>2</td>
<td>SJM 1084T</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>8</td>
<td>F</td>
<td>19.6</td>
<td>121</td>
<td>AVB III</td>
<td>Ventricular and atrial septal defects</td>
<td>1</td>
<td>MDT Starfix 4195 (CS)</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>7</td>
<td>M</td>
<td>19.9</td>
<td>123</td>
<td>AVB III</td>
<td>Idiopathic AVB</td>
<td>2</td>
<td>MDT 5076</td>
<td>MDT 5076</td>
</tr>
<tr>
<td>13</td>
<td>4</td>
<td>F</td>
<td>13.0</td>
<td>NA</td>
<td>AVB III</td>
<td>Ventricular septal defect and dextroposition of the great vessels</td>
<td>2</td>
<td>3830</td>
<td>3830</td>
</tr>
<tr>
<td>14</td>
<td>5</td>
<td>M</td>
<td>15.0</td>
<td>103</td>
<td>AVB III</td>
<td>Pulmonary artery stenosis</td>
<td>2</td>
<td>3830</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>10</td>
<td>F</td>
<td>27.0</td>
<td>141</td>
<td>VT</td>
<td>PCVT</td>
<td>2</td>
<td>MDT 5076</td>
<td>MDT 6935M-55cm</td>
</tr>
</tbody>
</table>

AVB = atrioventricular block; CS = coronary sinus; F = female; M = male; MDT=Medtronic; PCVT = polymorphic catecholergic ventricular tachycardia; SJM = St-Jude Medical; VT = ventricular tachycardia; 3830 = Medtronic SelectSecure 3830 lead
lis major muscle before implanting the second lead. After lead fixation, an absorbable haemostatic suture, which was initially placed at the beginning of the procedure around the 0.035” J-wires, was secured around the venous entrance point of the leads (owing to the mismatch between the diameters of the guiding catheter and of the lead that may cause bleeding).

Results

We retrieved data from 15 patients (7 males), median age 8 yr, interquartile range (IQR) 3–10 yr (range 2–15 yr) at the time of intervention, with a median weight of 19.8 kg, IQR 13.6–33 kg (range 11.3–38.0 kg), and with a median height of 118 cm, IQR 94–145 cm.

Two additional patients implanted via subclavian vein puncture by the cardiovascular surgeons with standard leads were not included in the analysis. The most common indication was symptomatic postoperative third-degree atrioventricular block in patients suffering from structural congenital heart disease. All devices were pacemakers apart from a single ICD (patient 15). Detailed patient information is listed in table 1. Two operators (H.B. and H.S.) placed 10 right atrial pacing leads, 13 right ventricular pacing leads, 1 right ventricular ICD lead and 1 coronary sinus pacing lead. Of these leads, a total of 18 SelectSecure 3830 leads were used for the procedures, including 8 right atrial and 10 right ventricular leads. Duration of fluoroscopy was 12.8 ± 9.8 min (range 5–35 min).

Table 2: Select Secure 3830 electrical parameters at implantation and at follow-up (mean 13.1 ± 22.7 months, range 0–68 months).

<table>
<thead>
<tr>
<th>At implantation</th>
<th>At follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensing (mV)</td>
<td>Capture thresholds (V@0.5 ms)</td>
</tr>
<tr>
<td>Right atrial lead (n = 8)</td>
<td>1.8 ± 1.0</td>
</tr>
<tr>
<td>Right ventricular lead (n = 9)</td>
<td>8.2 ± 3.4</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation.

Axillary vein puncture was successful in all patients in whom it was attempted, and there was no procedure-related complication (haemo/pneumothorax or lead dislodgement). In the patient in whom a single axillary vein puncture had been performed to introduce two 3830 leads, buckling with retraction of the ventricular lead by about 5 cm at the venous entry site resulted from friction with the atrial guiding catheter during its slitting. The ventricular lead was successfully reinserted into the vein without adverse events. Average loss of haemoglobin points was 0.7 ± 1.1 g/dl (range 0.11–3.4 g/dl). Lead electrical parameters were within normal limits for all leads at implantation and after a mean follow-up of 13 ± 23 months (range 0–68 months) and are shown in table 2.

Discussion

Many centres prefer implanting transvenous pacing leads in children weighing >10 kg rather than placing epicardial leads surgically. Our report indicates that contrast-guided axillary vein puncture for pacemaker and ICD lead implantation in children is safe, with a 100% success rate in our series, which is admittedly of small size. Axillary vein puncture in children has been previously reported in two series of 18 and 48 patients [4, 5], with a reported success rate of 94%–100%. Our patients were younger at implantation than the patients in these studies, with Silvetti et al. [4] reporting a mean age of 12 yr (range 2–18 yr), and Lee et al. [5] reporting a mean age of 9 yr (range 4–15 yr). We also report a lower body weight at implantation compared with these previous studies.

Axillary vein puncture is attractive because it is highly successful, safe (with minimal risk of pneumothorax or haemothorax), results in virtually no friction with the clavicle (facilitating lead placement and avoiding subclavian crush) and is easily learnt (it is taught to all device fellows at our institution). Contrast-guided puncture may, however, not be performed in patients who have contrast allergy or in whom it is impossible to insert an ipsilateral venous catheter. We and others have previously described fluoroscopic landmarks that allow axillary vein puncture in adults without contrast injection [6, 7], and another alternative is to use echo guidance [8], although these techniques have not as yet been reported in children. An alternative approach is cephalic venous cutdown, which has also been described in the paediatric population [9]. The advantages of ce-
phalic access is the low risk of subclavian crush and absence of risk of pneumothorax, but may be challenging to perform in small children as a result of the small size of the vein. The Select Secure 3830 lead is currently being used in adults for transseptal endocardial left ventricular pacing [10, 11] because it can be delivered via a catheter and its high flexibility avoids mitral valve dysfunction. Our report indicates that it may also be used safely in children for conventional pacing. Combining our data with those from three previous pediatric series [12–14], in a total of 98 patients, there have been no serious adverse events reported. In another series of 91 patients with congenital heart disease (and a mean age of 18 ± 8 yr) implanted with the Select Secure 3830 lead [15], there were no serious adverse events reported other than lead dislodgment in one patient. The 8.4F delivery catheter may be considered by some implanting physicians to be too large for this patient population, and alternative delivery methods using smaller guiding catheters have been tested [12, 14]. We, however, did not experience any problems using the deflectable catheter in our patients, and smaller fixed-shape catheters are now available for use with this lead. If multiple leads are implanted, it is advisable to perform separate sticks, as friction with the guiding catheter upon slitting may cause retraction of the first lead, as was the case in our patient in whom a single stick was performed [12, 14].

The SelectSecure 3830 lead does, however, have certain drawbacks. First, it is not (and probably never be) magnetic resonance imaging (MRI) conditional, as a result of its cable design. This could be a disadvantage in young patients with congenital heart disease, in whom this imaging modality may be very useful. However, most of our patients were referred from developing countries for surgical correction of congenital heart disease, in whom long-term lead performance (in an environment with minimal device follow-up) is more important than MRI conditionality. Second, there are no published data concerning percutaneous lead extraction of the SelectSecure 3830 lead. The absence of a lumen does not allow use of a locking stylet. However, the cable design of the lead means that it is extremely resistant to traction, as long as the insulation and conducting wires are sutured together if the IS-1 connector pin is cut to allow use of extraction sheaths. A Bulldog lead extender (Cook Medical) may be used to extend the lead if extraction sheaths are used. We have successfully and uneventfully extracted an atrial 3830 lead implanted for 7 years in a 11-year-old child, using only polypropylene sheaths (unpublished data).

Limitations
This is a small retrospective study, with all the caveats inherent to these limitations (i.e., incomplete data, inaccurate success and complication rates, etc.). Follow-up was limited by the fact that most children came from developing countries, and long-term performance of the lead (e.g., after the end of growth) is not available.

Conclusions
On the basis of our experience and previous reports, contrast-guided axillary vein puncture for lead implantation in paediatric patients is a safe and effective approach and has become the method of choice at our institution. The Medtronic SelectSecure 3830 lead is a good option in children, owing to its capability for selective-site pacing, small diameter, high flexibility, and excellent long-term performance. Absence of MRI conditionality and possible issues with lead extraction should nevertheless be borne in mind when opting for this solution.

Disclosures
Dr. Burri: research contracts, speaker honoraria and fellowship support with Medtronic.

References
A full list of references is available in the online version of this article.
References

10 Morgan JM, Scott PA, Turner NG, Yue AM, Roberts PR. Targeted left ventricular endocardial pacing using a steerable introducing guide catheter and active fixation pacing lead. Europace 2009;11:502–6.